Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
作者信息
Sait Sameer, Kobos Rachel, LaQuaglia Michael P, Pandit-Taskar Neeta, Modak Shakeel
机构信息
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York.
出版信息
Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26314. Epub 2016 Nov 2.
Abstract
Few effective therapeutic options exist for patients with metastatic paraganglioma (PGL). We report the case of a 16-year-old male who developed acute myeloid leukemia (AML) 30 months following the treatment for metastatic PGL. PGL had been refractory to I-meta-iodobenzylguanidine and temozolomide therapy. However, there was a major reduction in primary tumor allowing its gross total resection, and complete resolution of metastatic disease following AML-directed therapy that included daunorubicin, cytarabine, and etoposide. He remains in remission for both AML and PGL, 48 months post AML chemotherapy. Alternative chemotherapeutic agents should be considered for metastatic PGL resistant to conventional therapy.
摘要
相似文献
1
Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26314. Epub 2016 Nov 2.
2
Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Biomed Pharmacother. 2012 Dec;66(8):578-82. doi: 10.1016/j.biopha.2011.11.006. Epub 2011 Dec 21.
3
Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Leuk Res. 2006 Mar;30(3):296-302. doi: 10.1016/j.leukres.2005.06.026. Epub 2005 Aug 19.
4
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Ann Hematol. 2009 Feb;88(2):151-8. doi: 10.1007/s00277-008-0571-z. Epub 2008 Aug 16.
5
Acute myeloid leukemia complicating multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine.
Clin Lymphoma Myeloma. 2009 Aug;9(4):E14-5. doi: 10.3816/CLM.2009.n.066.
6
Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Acta Haematol. 2014;131(4):200-1. doi: 10.1159/000355134. Epub 2013 Nov 27.
7
[Consolidation of therapy of acute myeloid leukemia with the AML-BFM 93 protocol in children in the Czech Republic].
Cas Lek Cesk. 2004;143(4):257-63.
8
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Ann Hematol. 2014 Dec;93(12):2011-8. doi: 10.1007/s00277-014-2143-8. Epub 2014 Jul 4.
9
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
J Clin Oncol. 2001 May 15;19(10):2705-13. doi: 10.1200/JCO.2001.19.10.2705.
10
Etoposide in remission induction of adult acute myeloid leukemia.
Acta Haematol. 1990;83(2):82-5. doi: 10.1159/000205173.
引用本文的文献
1
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Front Endocrinol (Lausanne). 2022 Nov 9;13:1066208. doi: 10.3389/fendo.2022.1066208. eCollection 2022.
本文引用的文献
1
Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment.
Hematol Oncol Clin North Am. 2016 Feb;30(1):135-50. doi: 10.1016/j.hoc.2015.09.006. Epub 2015 Oct 23.
2
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Endocr Pract. 2016 Mar;22(3):302-14. doi: 10.4158/EP15725.OR. Epub 2015 Nov 2.
3
Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
Clin Endocrinol (Oxf). 2014 Nov;81(5):642-51. doi: 10.1111/cen.12542. Epub 2014 Jul 30.
4
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Int J Cancer. 2014 Dec 1;135(11):2711-20. doi: 10.1002/ijc.28913. Epub 2014 May 5.
5
Long-term prognosis of patients with pediatric pheochromocytoma.
Endocr Relat Cancer. 2013 Dec 16;21(1):17-25. doi: 10.1530/ERC-13-0415. Print 2014 Feb.
6
SDH mutations establish a hypermethylator phenotype in paraganglioma.
Cancer Cell. 2013 Jun 10;23(6):739-52. doi: 10.1016/j.ccr.2013.04.018. Epub 2013 May 23.
7
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Neuro Oncol. 2013 Oct;15(10):1445-50. doi: 10.1093/neuonc/not036. Epub 2013 Mar 21.
8
Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
Biol Blood Marrow Transplant. 2012 Mar;18(3):473-80. doi: 10.1016/j.bbmt.2011.11.009. Epub 2011 Nov 10.
9
Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.
Cancer. 2012 Jun 1;118(11):2804-12. doi: 10.1002/cncr.26577. Epub 2011 Oct 17.
10
Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.
J Biomed Biotechnol. 2011;2011:104631. doi: 10.1155/2011/104631. Epub 2011 May 3.
Zotero 插件